孟鲁司特治疗感染后咳嗽的临床分析

Clinical Analysis of Montelukast in the Treatment of Post-infectious Cough

目的:观察乙酰半胱氨酰白三烯受体拮抗药孟鲁司特治疗感染后咳嗽的疗效。方法:89例感染后咳嗽患者随机分为治疗组与对照组,治疗组口服孟鲁司特+红霉素,对照组口服酮替芬+红霉素,并根据咳嗽评分评价临床疗效。结果:治疗组治疗前、后咳嗽评分为1.89±0.73、0.53±0.19(P<0.05);对照组治疗前、后咳嗽评分为1.79±0.80、1.23±0.36(P>0.05);2组治疗后咳嗽评分比较,差异有统计学意义(P<0.05)。治疗组与对照组的总有效率分别为80.00%、47.73%(P<0.05)。结论:孟鲁司特治疗感染后咳嗽效果好,可在临床推广。

OBJECTIVE： To observe the clinical efficacy of acetyl cysteinyl leukotriene receptor antagonist-Montelukast for post-infectious cough. METHODS： 89 patients with post-infectious cough were randomized into treatment group and control group. Treatment group was treated with montelukast and erythromycin, and control group was treated with ketotifen and erythromycin. The clinical efficacy was evaluated according to cough scores. RESULTS： The cough scores before and after treatment for treatment group were 1.89±0.73 and 0.53±0.19（P0.05）, and for control group were 1.79±0.80 and 1.23±0.36（P0.05）. There was significant difference between two groups. Total effective rate of two groups were 80.00% and 47.73%（P0.05）. CONCLUSION： Montelukast is effective for post-infectious cough and it is worthy of spreading in the clinic.